Development Of An Off-The-Shelf γδ T-Cell Platform For Allogenic Cell Therapies

Adoptive cell therapies like CAR and TCR-based approaches continue to reshape oncology, but allogeneic, off-the-shelf platforms are gaining traction for their scalability and accessibility. Among these, γδ T cells stand out due to their HLA independence, innate anti-tumor activity, and compatibility with advanced engineering techniques. This webinar dives into the unique advantages of γδ T cells and the challenges of developing allogeneic therapies, including immune rejection and persistence.

Gain a deeper understanding of how gene-editing and receptor redirection strategies are being used to enhance therapeutic performance, as well as explore how next-generation cell therapy platforms are being built.